Article Listing - Strong Ph III data on AstraZeneca/B-MS’s dapagliflozin

GAMBRO PRETAX EARNINGS JUMP 46%

16 March 1992

Swedish company Gambro reported sales up 12.9% to 5.62 billion Swe-dish kroner ($943.8 million) for 1991, and pretax earnings of...

HOECHST DEFENDS NOMIFENSINE IN SUIT

16 March 1992

The German drugs major Hoechst AG is defending itself against allegations linked to claimed side effects of the company's antidepressant...

MEVACOR WORKS IN FDB, SAYS STUDY

16 March 1992

Familial defective apolipoprotein B-100 (FDB), an autosomal dominant disorder characterized by hyper-cholesterolemia, has been shown to be responsive to treatment...

US ORPHAN DRUG CHANGE "WOULD BE VETOED"

16 March 1992

The US Bush Administration is strongly opposed to S 2060, the Senate legislation which proposes to end the market monopoly...

HANTAREX BIOMED LINK WITH SMA?

16 March 1992

A new alliance with possible developments in the biomedical sector has been set up recently in Italy. Under a preliminary...

LIFEGrOUP CHANGES ACQUISITION PLAN

16 March 1992

After a long period of analysis and negotiation, Italy's LIFEGROUP, founded in 1991, has decided against proceeding with the planned...

BEECHAM WITHDRAWS TALPEN FROM UK

16 March 1992

- Beecham Pharma has withdrawn the broad spectrum penicillin antibiotic Talpen (talampicillin hydrochloride) from the UK market on grounds that...

BBG'S DETECTION KITS

16 March 1992

- British Bio-technology Prod-ucts Ltd has expanded its range of in situ hybridization products to include a Detection Module for...

TREATMENT IND FOR AGOURON'S AG-331

16 March 1992

- Oncologists have confirmed that USA-based Agouron Phar-ma's AG-331 has been effective against tumors in animals. The company plans to...

GENZYME AND GLYCOPROTEINS

16 March 1992

- Genzyme Corp, in collaboration with Robert Van Etten and colleagues at Purdue University, Indiana, has developed technol-ogy which could...

Showing 94821-94830 of 95572 articles